NasdaqHealth CarePharmaceutical PreparationsCAMBRIDGE, MA

Parabilis Medicines, Inc. PBLS

Ask your AI

Estimated market cap $3.56B125.26M shares, shares as of Nov 9, 2026CIK 1657677

Insider trades, 12 mo

14 buys · 0 sells

$441.42M bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

29.2% of shares · 16 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Parabilis Medicines, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Parabilis Medicines, Inc.'s latest quarterly report, compared with the one before.

Loading…

IPO prospectus

Priced

Parabilis Medicines, Inc.’s initial public offering: where it stands and what the registration statement says.

Priced · Proposed ticker PBLS, Nasdaq Global Select Market · First filed May 19, 2026 · Priced Jun 10, 2026

Raised

$670.0M

price times shares, before any over-allotment

Price per share

$20.00

on the final prospectus

Shares offered

33.50M

base offering

Read from the S-1/A filed Jun 9, 2026 · Read it on sec.gov ↗

Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.

AI summary of the prospectus. Written by AI from the parts of the prospectus listed in the filing, and checked against its text. This is information, not investment advice.

All filings of this IPO Read the S-1/A on sec.gov ↗

IPO prospectus

Parabilis Medicines, Inc.’s initial public offering: where it stands and what the registration statement says.

Loading…

Insider trades

14 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jul 22, 2026. Insiders have two business days to file.

Recent insider trades

Ra Capital Management, L.P. Director, 10% owner	Jul 22 Form 4 ↗	Buy	+$1.4M 47,250 sh @ $29.77	-8.7%
Ra Capital Management, L.P. Director, 10% owner	Jul 21 Form 4 ↗	Buy	+$1.1M 37,723 sh @ $30.00	-6.2%
Ra Capital Management, L.P. Director, 10% owner	Jul 21 Form 4 ↗	Buy	+$189.7K 6,504 sh @ $29.17	-6.2%
Ra Capital Management, L.P. Director, 10% owner	Jul 21 Form 4 ↗	Buy	+$606.6K 21,696 sh @ $27.96	-6.2%
Ra Capital Management, L.P. Director, 10% owner	Jul 20 Form 4 ↗	Buy	+$914.4K 32,987 sh @ $27.72	+2.4%

All PBLS insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

36.15M shares

75 funds report PBLS. Values checked against market prices.

Q3 2026. 40 new, 16 added to, 6 trimmed, 44 exited since Q2 2026.

Top 13F holders
#
1	FMR LLC 13F ↗	10.87M	$336.6M	+5.6%
2	Alphabet Inc. 13F ↗	4.92M	$158.9M	unchanged
3	Regeneron Pharmaceuticals, Inc. 13F ↗	4.17M	$134.5M	unchanged
4	Siren, LLC 13F ↗	2.99M	$96.6M	unchanged
5	BlackRock, Inc. 13F ↗	2.79M	$90.1M	New
6	Vanguard Portfolio Management LLC 13F ↗	1.58M	$51.1M	+21.5%
7	Vanguard Capital Management LLC 13F ↗	1.56M	$50.3M	+34.5%
8	General Atlantic, L.P. 13F ↗	1.54M	$49.7M	unchanged
9	JPMorgan Chase & Co 13F ↗	1.06M	$33.9M	+1.9%
10	Geode Capital Management, LLC 13F ↗	1.00M	$32.5M	+911.4%

Download CSV Every fund that holds PBLS, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Parabilis Medicines, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Parabilis Medicines, Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at Parabilis Medicines, Inc.

1 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to Parabilis Medicines, Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at Parabilis Medicines, Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	0	0	0
2025 Q1	0	0	0
2025 Q2	1	1	1
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	1	1	1

Most common job titles at Parabilis Medicines, Inc.
Job title	Applications	Median wage
Scientist II	1	—

All PBLS applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2026	79	—	98.97M	$2.7B
Q3 2026	75	-4	36.15M	$1.2B

Each point is a quarter-end, from Q2 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (698955101). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes3 in 12 mo 8-K events5 in 90 days Patents3 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Parabilis Medicines, Inc.
Address: 30 ACORN PARK DRIVE, 6TH FLOOR, CAMBRIDGE, MA 02140
Phone: 617-945-9510
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: PBLS (Nasdaq)
Former names: FOG PHARMACEUTICALS, INC. (until 2022)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$28.43+$0.74 (+2.67%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $22.75 · High $30.37Nov 13, 2026

Aug 13, 2026Low $22.75 · High $41.73Nov 13, 2026

Jun 10, 2026Low $22.75 · High $41.73Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.